Has Teena Bhatla received payments from drug or device companies?

Yes. Drug and device makers reported $2,650 in general payments to Teena Bhatla across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Teena Bhatla did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Teena Bhatla come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Teena Bhatla

Pediatric Hematology-Oncology · New York, NYNPI 1457539900

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,725 of the $2,650 with a category attached, or 65.1%. Y-mabs Therapeutics, Inc. accounts for 65.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $1,814 and has fallen 78.3% since, to $394 in 2025.

$2,650in general payments, 2019–2025

Across 43 payments — averaging $61.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Y-mabs Therapeutics, Inc.$2K
Pfizer$198
Servier Pharmaceuticals LLC$168
Sobi, Inc$144
Emmaus Medical, Inc.$82
Agios Pharmaceuticals, Inc.$60
plus $274 from 11 others

$379,319in research payments, 2019–2025

Across 50 payments — averaging $7586.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Jazz Pharmaceuticals Inc.$365K
Janssen Research & Development, LLC$9K
Incyte Corporation$5K

What the payments were for

Consulting fees$1,72565%
Food & beverage$92535%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Y-mabs Therapeutics, Inc.	1	$1,725
Pfizer	9	$198
Servier Pharmaceuticals LLC	10	$168
Sobi, Inc	2	$144
Emmaus Medical, Inc.	4	$82
Agios Pharmaceuticals, Inc.	3	$60
Adaptive Biotechnologies Corporation	2	$45
Azurity Pharmaceuticals, Inc.	2	$36
Springworks Therapeutics, Inc.	2	$30
Amgen	1	$27
Astellas Pharma US Inc	1	$24
Novartis	1	$23
RARE Disease Therapeutics, Inc.	1	$22
Jazz Pharmaceuticals Inc.	1	$20
Day One Biopharmaceuticals	1	$18
Kedrion Biopharma, Inc.	1	$16
Argon Medical Devices, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DANYELZA$1,725
Gamifant$125

How this compares

$2,650 in reported general payments places this provider in the 65th percentile of 196 pediatric hematology-oncology providers in New York.

See all pediatric hematology-oncology providers in New York →

Other pediatric hematology-oncology in New York

Sujit ShethNew York$359K
Jaap Jan BoelensNew York$303K
James BusselNew York$204K
Saara KavianyNew York$144K
Gary BrittenhamNew York$137K
James FerraraNew York$118K
John LevineNew York$98K
Nai-Kong CheungNew York$86K
Andrew HarrisNew York$85K
Joseph OvedNew York$77K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →